Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
3 days agoVaccine Innovator VitriVax Raises $17.25 Million Series B to Advance Stable Formulations
Biotech startup VitriVax closed a $17.25 million Series B round to expand its heat-stable vaccine formulation platform aimed at global distribution without cold-chain requirements. The company plans to scale clinical manufacturing and advance trials for multiple immunizations, including malaria and influenza. CEO Dr. Drew McCall said the technology could cut distribution costs by up to 60%. Investors include health-impact funds and strategic pharma partners. Analysts expect VitriVax’s approach to transform last-mile vaccine delivery in developing markets and support pandemic-preparedness initiatives backed by global health agencies.
Explore:Mutual Fund Screening
positive
3 days agoVaccine Innovator VitriVax Raises $17.25 Million Series B to Advance Stable Formulations
Biotech startup VitriVax closed a $17.25 million Series B round to expand its heat-stable vaccine formulation platform aimed at global distribution without cold-chain requirements. The company plans to scale clinical manufacturing and advance trials for multiple immunizations, including malaria and influenza. CEO Dr. Drew McCall said the technology could cut distribution costs by up to 60%. Investors include health-impact funds and strategic pharma partners. Analysts expect VitriVax’s approach to transform last-mile vaccine delivery in developing markets and support pandemic-preparedness initiatives backed by global health agencies.
Explore:Mutual Fund Screening
positive
Vaccine Innovator VitriVax Raises $17.25 Million Series B to Advance Stable Formulations
4 days ago
1 min read
85 words
VitriVax secured $17.25 million to scale heat-resistant vaccine technology, targeting cost-efficient global distribution and expanded clinical trials for key infectious diseases.
Biotech startup VitriVax closed a $17.25 million Series B round to expand its heat-stable vaccine formulation platform aimed at global distribution without cold-chain requirements. The company plans to scale clinical manufacturing and advance trials for multiple immunizations, including malaria and influenza. CEO Dr. Drew McCall said the technology could cut distribution costs by up to 60%. Investors include health-impact funds and strategic pharma partners. Analysts expect VitriVax’s approach to transform last-mile vaccine delivery in developing markets and support pandemic-preparedness initiatives backed by global health agencies.
Biotech startup VitriVax closed a $17.25 million Series B round to expand its heat-stable vaccine formulation platform aimed at global distribution without cold-chain requirements. The company plans to scale clinical manufacturing and advance trials for multiple immunizations, including malaria and influenza. CEO Dr. Drew McCall said the technology could cut distribution costs by up to 60%. Investors include health-impact funds and strategic pharma partners. Analysts expect VitriVax’s approach to transform last-mile vaccine delivery in developing markets and support pandemic-preparedness initiatives backed by global health agencies.
Companies:
VitriVax
Tags:
startups
biotech
startups
biotech
funding
healthcare
VitriVax
Oct 27, 2025 • 04:19 IST